Related Experiment Video
Updated: Sep 17, 2025

Assessment of Antibody-based Drugs Effects on Murine Bone Marrow and Peritoneal Macrophage Activation
Published on: December 26, 2017
Risk Factors Associated With Thrombocytopenia Induced by Intravenous Immunoglobulin Formulations: An Analysis Using
Yoshihiro Nishita1,2, Natsuko Ishida3, Hirofumi Nagai2
1Clinical Pharmacy and Healthcare Science, Kanazawa University, Kanazawa, Japan; yoshi-n@kanazawa-med.ac.jp.
Intravenous immunoglobulin (IVIg) can cause thrombocytopenia. Elderly patients and those with immune-mediated skin or muscular diseases face a higher risk of this adverse event.
Area of Science:
- Pharmacovigilance
- Immunology
- Hematology
Background:
- Thrombocytopenia is a known adverse event associated with intravenous immunoglobulin (IVIg) formulations.
- Previous reports were limited to individual case studies, lacking epidemiological data.
- This study addresses the need for epidemiological investigation into IVIg-induced thrombocytopenia.
Purpose of the Study:
- To investigate the risk of thrombocytopenia associated with IVIg.
- To identify factors contributing to IVIg-induced thrombocytopenia.
- To analyze IVIg adverse event data from a large Japanese database.
Main Methods:
- Utilized Japanese Adverse Drug Event Report database from April 2004 to August 2024.
- Employed reporting odds ratio (ROR) to assess the association between IVIg and thrombocytopenia.
- Applied multiple logistic regression to identify associated factors, including age, sex, formulation, and disease group.
Main Results:
- A significant association was found between IVIg use and thrombocytopenia.
- Pemphigoid, Kawasaki disease, and polymyositis/dermatomyositis were frequently reported diseases.
- Increased risk of thrombocytopenia was observed in patients aged 60 and older, and those with immune-mediated skin and muscular diseases.
Conclusions:
- Intravenous immunoglobulin (IVIg) is associated with an increased risk of thrombocytopenia.
- Clinical assessment for thrombocytopenia is recommended for elderly patients.
- Patients with immune-mediated skin and muscular diseases require careful monitoring during IVIg therapy.
Related Concept Videos
Factors Affecting Protein-Drug Binding: Patient-Related Factors
Age stands as a key determinant in protein-drug binding. Neonates, characterized by low albumin content, experience heightened concentrations of unbound drugs such as phenytoin and...
Blood Transfusion and Agglutination
History
The history of blood transfusion dates back to the 17th century, when early attempts were made in animals. In 1818 James Blundell, a British doctor, performed the first successful human blood transfusion. Later in 1900, Karl...
Disorders of Hemostasis
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Factors Affecting Protein-Drug Binding: Drug-Related Factors
One crucial factor in drug-protein binding is the drug's lipophilicity or its affinity for fat. More lipophilic drugs tend to have higher binding extents. For example, highly lipophilic drugs like cloxacillin exhibit substantial protein binding, with as much as 95% of the drug binding to proteins. In...
Acute Kidney Injury IV: Diagnostic Studies and Prevention
Factors Affecting the Risk of Infection
The integrity and count of the white blood cells help the body resist pathogens and fight infection. When impaired, it reduces the body's resistance to pathogens. The acidic pH levels of the gastrointestinal, genitourinary tracts, and skin...

